Novartis and WHO Extend Partnership to Eliminate Leprosy, Treat 1 Million More by 2030
ByAinvest
Wednesday, Feb 4, 2026 7:39 am ET1min read
NVS--
Novartis and WHO have renewed their partnership to eliminate leprosy, aiming to treat one million more people by 2030 and prevent countless new cases. The partnership has already reduced cases by over 95% since the introduction of multidrug therapy in the 1980s. Novartis will provide MDT globally at no cost and funding for a compound to serve as post-exposure prophylaxis.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet